The Liver-Heart Axis: A Narrative Review of Clinical Implications of the MASLD Redefinition for Internists
ASIDE Gastroenterology · 18.03.2026 · 2 (2) · 26-42
DOI: 10.71079/aside.gi.031826446 ↗Kurz gefasst
Fachartikel in der Zeitschrift ASIDE Gastroenterology, online erschienen am 18.03.2026. Verfasst von Hassan A. Abdou und 1 weiteren Autor:innen. Die Arbeit nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Metabolically-dysfunction-associated steatotic liver disease (MASLD) represents a paradigm shift emphasizing the metabolic underpinnings of hepatic steatosis and its systemic consequences. MASLD carries a substantial cardiovascular burden. This review examines the clinical implications of the MASLD redefinition for internists, with particular focus on the liver-heart axis.
Methods
We conducted a narrative review synthesizing evidence through December 2024. Literature searches were performed in PubMed, EMBASE, and Cochrane Library using terms including "MASLD," "nonalcoholic fatty liver disease," "metabolic dysfunction-associated steatohepatitis, "cardiovascular disease," and "cardiometabolic risk." Priority was given to systematic reviews, meta-analyses, and large prospective cohort studies.
Results
MASLD is associated with increased risks of coronary artery disease, myocardial infarction, heart failure with preserved ejection fraction, atrial fibrillation, and cardiovascular mortality. These associations are mediated through insulin resistance, chronic inflammation, oxidative stress, atherogenic dyslipidemia, hepatokine dysregulation, gut-derived metabolites, and genetic determinants — though substantial residual confounding by shared cardiometabolic risk factors remains. Hepatic fibrosis stage emerges as a critical amplifier of cardiovascular risk. Integrated management requires systematic case-finding, fibrosis risk stratification using validated noninvasive tools, comprehensive cardiovascular assessment, intensive lifestyle intervention, and pharmacotherapy including incretin-based therapies, sodium-glucose cotransporter-2 inhibitors, and statins.
Conclusions
Internists must adopt integrated approaches addressing both hepatic and cardiovascular manifestations of MASLD. The liver-heart axis requires recognition as an interconnected system, with cardiovascular risk management prioritized alongside hepatic care. While the MASLD nomenclature is intended to improve disease recognition and patient engagement, prospective validation of these anticipated benefits remains needed.
Zitieren
APA
Abdou, H. A., & Omar, S. A. (2026). The Liver-Heart Axis: A Narrative Review of Clinical Implications of the MASLD Redefinition for Internists. ASIDE Gastroenterology, 2(2), 26-42. https://doi.org/10.71079/aside.gi.031826446
Vancouver
Abdou HA, Omar SA. The Liver-Heart Axis: A Narrative Review of Clinical Implications of the MASLD Redefinition for Internists. ASIDE Gastroenterology. 2026;2(2):26-42. doi:10.71079/aside.gi.031826446
BibTeX
@article{Abdou2026,
author = {Abdou, Hassan A. and Omar, Saied A.},
title = {The Liver-Heart Axis: A Narrative Review of Clinical Implications of the MASLD Redefinition for Internists},
journal = {ASIDE Gastroenterology},
year = {2026},
volume = {2},
number = {2},
pages = {26--42},
doi = {10.71079/aside.gi.031826446}
}
EUVIMED